A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells

Journal of Controlled Release

Volumn 149, Issue 2, 2011, Pages 196-205

  Kopecka, Joanna ^a   Campia, Ivana ^a   Olivero, Paolo ^a   Pescarmona, Gianpiero ^a   Ghigo, Dario ^a   Bosia, Amalia ^a   Riganti, Chiara ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Doxorubicin; LDL receptor; Liposomes; P glycoprotein; Simvastatin

Indexed keywords

ADVERSE EFFECT; ANTICANCER DRUG; BINDING PEPTIDE; CHOLESTEROL SYNTHESIS; COLON CANCER; CYTOTOXIC EFFECTS; DOXORUBICIN; DRUG RESISTANCE; HUMAN CANCER CELLS; LDL RECEPTOR; LIPOSOMAL DOXORUBICIN; LOW DENSITY LIPOPROTEINS; P-GLYCOPROTEIN; PLASMA MEMBRANES; PUMP FUNCTION; RESISTANT CELLS; SIMVASTATIN; STATINS;

CELL MEMBRANES; CHOLESTEROL; LIPOSOMES; PHOSPHOLIPIDS; PUMPS;

GLYCOPROTEINS;

APOLIPOPROTEIN B100; ASPARTYLTRYPTOPHYLLEUCYLLYSYLALANYLPHENYLALANYLTYROSYLASPARTYLLYSYLVALYLALANYLGLUTAMYLLYSYLLEUCYLLYSYLGLUTAMYLALANYLPHENYLALANYLARGINYLLEUCYLTHREONYLARGINYLLYSYLARGINYLGLYCYLLEUCYLLYSYLLEUCYLALANINE; BINDING PROTEIN; CHOLESTEROL; DOXORUBICIN; GLYCOPROTEIN P; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; METHYL BETA CYCLODEXTRIN; RECOMBINANT RECEPTOR; SIMVASTATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL MEMBRANE; CELL STRAIN HT29; CHOLESTEROL SYNTHESIS; CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; ENDOCYTOSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

AMINO ACID SEQUENCE; ANTIBIOTICS, ANTINEOPLASTIC; APOLIPOPROTEIN B-100; BINDING SITES; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CHOLESTEROL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HT29 CELLS; HUMANS; LIPOSOMES; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECEPTORS, LDL; RECOMBINANT PROTEINS;

EID: 78651360819     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.10.003     Document Type: Article

References (36)

1. K. Takara, T. Sakaeda, and K. Okumura An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy Curr. Pharm. Des. 12 2006 273 286
2. C.L. Shapiro, and A. Recht Side effects of adjuvant treatment of breast cancer N Engl J. Med. 344 2001 1997 2008
3. E. Borowski, M.M. Bontemps-Gracz, and A. Piwkowska Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells Acta Biochim. Polonica 52 2005 609 627
4. C. Riganti, E. Miraglia, D. Viarisio, C. Costamagna, G. Pescarmona, D. Ghigo, and A. Bosia Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux Cancer Res. 65 2005 516 525
5. C. Riganti, S. Orecchia, G. Pescarmona, P.G. Betta, D. Ghigo, and A. Bosia Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma Int. J. Cancer 119 2006 17 27
6. Y. Lavie, G. Fiucci, M. Czarny, and M. Liscovitch Changes in membrane microdomains and caveolae constituents in multidrug-resistant cancer cells Lipids 34 1999 S57 S63
7. J. Troost, H. Lindenmaier, W.E. Haefeli, and J. Weiss Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells Mol. Pharmacol. 66 2004 1329 1332
8. Y. Kimura, N. Kioka, H. Kato, M. Matsuo, and K. Ueda Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol Biochem. J. 401 2007 597 605
9. P.D.W. Eckford, and F.J. Sharom Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity Drug Binding Transp. Biochem. 47 2008 13686 13698
10. L. Gayet, G. Dayan, S. Barakat, S. Labialle, M. Michaud, S. Cogne, A. Mazane, A.W. Coleman, D. Rigal, and L.G. Baggetto Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells Biochemistry 44 2005 4499 4509
11. A. Candoni, A. Michelutti, E. Simeone, D. Damiani, M. Baccarani, and R. Fanin Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance related proteins Eur. J. Haematol. 77 2006 293 299
12. M. Markman Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary Expert Opin. Pharmacother. 7 2006 1469 1474
13. L. Rajendran, H.J. Knölker, and K. Simons Subcellular targeting strategies for drug design and delivery Nat. Rev. Drug Discov. 9 2010 29 42
14. M. Nikanjam, E.A. Blakely, K.A. Bjornstad, X. Shu, T.F. Budinger, and T.M. Forte Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme Int. J. Pharm. 328 2007 86 94 (Pubitemid 44827556)
15. J.K. Liao, and U. Laufs Pleiotropic effects of statins Annu. Rev. Pharmacol. Toxicol. 45 2005 89 118
16. C.C. Allain, L.S. Poon, C.S. Chan, W. Richmond, and P.C. Fu Enzymatic determination of total serum cholesterol Clin. Chem. 20 1974 470 475
17. B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system Physiol. Rev. 86 2006 1179 1236
18. H.L. Wong, R. Bendayan, A.M. Rauth, and X.Y. Wu Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers J. Pharm. Sci. 93 2004 1993 2008
19. S.W. Provencher A constrained regularization method for inverting data represented by linear algebraic or integral equations Comput. Phys. Commun. 27 1982 213 227
20. TM Breast 18 2009 218 224
21. E. Wang, C.N. Casciano, R.P. Clement, and W.W. Johnson HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein Pharmacol. Res. 18 2001 800 806
22. P.G. Yancey, W.V. Rodriguez, E.P.C. Kilsdonk, G.W. Stoudt, W.J. Johnson, M.C. Phillips, and G.H. Rothblat Cellular cholesterol efflux mediated by cyclodextrins J. Biol. Chem. 271 1996 16026 16034
23. S. Belli, P.M. Elsener, H. Wunderli-Allenspach, and S.D. Kramer Cholesterol-mediated activation of P-glycoprotein: distinct effects on basal and drug-induced ATPase activities J. Pharm. Sci. 98 2009 1905 1918
24. L. Connelly-Smith, J. Pattinson, M. Grundy, S. Shang, C. Seedhouse, N. Russell, and M. Pallis P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors Exp. Hematol. 35 2007 1793 1800
25. E. Sieczkowski, C. Lehner, P.F. Ambros, and M. Hohenegger Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells Int. J. Cancer 126 2010 2025 2035
26. C. Chen, R.J. Mireles, S.D. Campbell, J. Lin, J.B. Mills, J.J. Xu, and T.A. Smolarek Differential interaction of 3-hydroxy-3-methylglutaryl-coA reductase inhibitors with ABCB1, ABCC2, and OATP1B1 Drug Metab. Dispos. 33 2005 537 546
27. I. Campia, C. Lussiana, G. Pescarmona, D. Ghigo, A. Bosia, and C. Riganti Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis Br. J. Pharmacol. 158 2009 1777 1786
28. A. Corsini, S. Bellosta, R. Baetta, R. Fumagalli, R. Paoletti, and F. Bernini New insights into the pharmacodynamic and pharmacokinetic properties of statins Pharmacol. Ther. 84 1999 413 428
29. L. Marcoff, and P.D. Thompson The role of coenzyme Q10 in statin associated myopathy. A systematic review J. Am. Coll. Cardiol. 49 2007 2231 2237
30. D.R. Budman, J. Tai, and A. Calabro Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro Breast Cancer Res. Treat. 104 2007 93 101
31. R. Schmidmaier, P. Baumann, I. Bumeder, G. Meinhardt, C. Straka, and B. Emmerich First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma Eur. J. Haematol. 79 2007 240 243
32. D.I. Kang, H.K. Kang, H.S. Gwak, H.K. Han, and S.J. Lim Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells Drug Deliv. 16 2009 261 267
33. T.L. Andresen, S.S. Jensen, and K. Jørgensen Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release Prog. Lipid Res. 44 2005 68 97
34. H.R. Kim, K. Andrieux, S. Gil, M. Taverna, H. Chacun, D. Desmaele, F. Taran, D. Georgin, and P. Couvreur Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis Biomacromolecules 8 2007 793 799
35. A.R. Thierry, D. Vigè, S.S. Coughlin, J.A. Belli, A. Dritschilo, and A. Rahaman Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes FASEB J. 7 1993 572 579
36. Z.G. Gao, D.H. Lee, D.I. Kim, and Y.H. Bae Doxorubicin-loaded pH sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice J. Drug Target. 13 2005 391 397